Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 3/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2839139 | 0.89 | CTSK (0.37) | LPAR1LPAR2LPAR3TRPA1MME | |
| SCHEMBL16060874 | 0.88 | LPAR1 (0.42) | LPAR1LPAR2LPAR3P2RX7ITGB1 | |
| SCHEMBL16496502 | 0.86 | ALOX5 (0.40) | LPAR1LPAR2LPAR3P2RX7ALOX5 | |
| SCHEMBL11896374 | 0.85 | MAPT (0.39) | P2RX7TSHRMAPTKMT2A | |
| SCHEMBL2762347 | 0.85 | LPAR1 (0.41) | LPAR1LPAR2LPAR3P2RX7ALOX5 | |
| SCHEMBL2839111 | 0.85 | LPAR1 (0.41) | LPAR1LPAR2LPAR3P2RX7ALOX5 | |
| SCHEMBL2837769 | 0.80 | P2RX7 (0.37) | LPAR1LPAR2LPAR3P2RX7MME | |
| SCHEMBL2836944 | 0.78 | KMT2A (0.38) | LPAR1LPAR2LPAR3P2RX7TSHR | |
| SCHEMBL16496187 | 0.77 | LPAR1 (0.36) | LPAR1LPAR2LPAR3P2RX7KDM4E | |
| SCHEMBL2762720 | 0.77 | TRPA1 (0.38) | LPAR1LPAR3TRPA1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358688-B1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | claimed |
| US-8440707-B2 | Antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | claimed |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | claimed |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | claimed |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | claimed |
| US-20150164874-A1 | PIRFENIDONE AND ANTI-FIBROTIC THERAPY IN SELECTED PATIENTS | INTERMUNE, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2358688-B1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8440707-B2 | Antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR2 2/4885LPAR3 5/4885 |
| US-20150164874-A1 | PIRFENIDONE AND ANTI-FIBROTIC THERAPY IN SELECTED PATIENTS | FIBP, PTGFR, MMP1 | LPAR1 1534/4885LPAR2 1143/4885LPAR3 747/4885 |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR2 2/4885LPAR3 5/4885 |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR2 2/4885LPAR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.